![]() ![]() He Y, Wheatley K, Clark O, Glasmacher A, Ross H, Djulbegovic B. Risk of disease progression in asymptomatic multiple myeloma. 33 (26):2863-9.ĭimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Palumbo A, Avet-Loiseau H, Oliva S, et al. International staging system for multiple myeloma. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. A clinical staging system for multiple myeloma. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. ![]() Shortt CP, Gleeson TG, Breen KA, McHugh J, O'Connell MJ, O'Gorman PJ, et al. Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma. ![]() International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. 158(17):1889-93.ĭimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. 100(1):107-13.īladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. 23(36):9219-26.īlimark C, Holmberg E, Mellqvist UH, Landgren O, Björkholm M, Hultcrantz M, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 19-Medical Research Council Adult Leukaemia Working Party. 80(3):733-7.Īugustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. 111(8):4039-47.īataille R, Boccadoro M, Klein B, Durie B, Pileri A. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, et al. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Accessed: January 13, 2023.Īilawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T, et al. Surveillance, Epidemiology, and End Results Program. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Multiple myeloma-an update on diagnosis and treatment. 171(6):637-45.Ĭaers J, Vande broek I, De Raeve H, Michaux L, Trullemans F, Schots R, et al. A nested case-control study of multiple myeloma risk and uranium exposure among workers at the Oak Ridge Gaseous Diffusion Plant. Yiin JH, Anderson JL, Daniels RD, Seel EA, Fleming DA, Waters KM, et al. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Use of hair colouring products and risk of multiple myeloma among US women. Koutros S, Baris D, Bell E, Zheng T, Zhang Y, Holford TR, et al. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Ludwig H, Drach J, Graf H, Lang A, Meran JG. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Molecular pathogenesis of multiple myeloma and its premalignant precursor. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells. Van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. Role of autologous and allogeneic stem cell transplantation in myeloma. Myeloma today: Disease definitions and treatment advances. ![]() NCCN Clinical Practice Guidelines in Oncology, Multiple Myeloma. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Management of Multiple Myeloma–related Bone Diseaseĭimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, et al.Chimeric antigen receptor (CAR) T-Cell Therapy.Beta-2 Microglobulin and C-Reactive Protein.Quantitative Immunoglobulin Levels (IgG, IgA, IgM). ![]()
0 Comments
Leave a Reply. |